AFFIRM-AL And Alzheimer's Trials Will Unlock New Opportunities

Published
26 Mar 25
Updated
24 Jul 25
AnalystConsensusTarget's Fair Value
US$24.29
65.5% undervalued intrinsic discount
24 Jul
US$8.38
Loading
1Y
-61.9%
7D
-1.8%

Author's Valuation

US$24.3

65.5% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 53%

Shared on24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 81.7x to 91.2x.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 113%

AnalystConsensusTarget has decreased revenue growth from 23.1% to 16.4%, increased profit margin from 10.5% to 19.3%, increased future PE multiple from 58.3x to 81.4x and increased shares outstanding growth rate from 0.0% to 0.0%.